Cargando…

Shiga toxin and its use in targeted cancer therapy and imaging

Shiga and the Shiga‐like toxins are related protein toxins produced by Shigella dysenteriae and certain strains of Escherichia coli. These toxins are composed of two non‐covalently attached, modular parts: the A moiety (StxA) containing the enzymatically active A(1) fragment, and the non‐toxic, pent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engedal, Nikolai, Skotland, Tore, Torgersen, Maria L., Sandvig, Kirsten
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023029/ https://www.ncbi.nlm.nih.gov/pubmed/21255370 http://dx.doi.org/10.1111/j.1751-7915.2010.00180.x

Ejemplares similares

Protection against Shiga Toxins
por: Kavaliauskiene, Simona, et al.
Publicado: (2017)

The Protein Toxins Ricin and Shiga Toxin as Tools to Explore Cellular Mechanisms of Internalization and Intracellular Transport
por: Sandvig, Kirsten, et al.
Publicado: (2021)

Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding
por: Ailte, Ieva, et al.
Publicado: (2016)

Cell-Penetrating Peptides: Possibilities and Challenges for Drug Delivery in Vitro and in Vivo
por: Skotland, Tore, et al.
Publicado: (2015)

Geldanamycin Enhances Retrograde Transport of Shiga Toxin in HEp-2 Cells
por: Lingelem, Anne Berit Dyve, et al.
Publicado: (2015)

The role of PS 18:0/18:1 in membrane function
por: Skotland, Tore, et al.
Publicado: (2019)

The role of lipid species in membranes and cancer-related changes
por: Skotland, Tore, et al.
Publicado: (2020)

The anti-tumor drug 2-hydroxyoleic acid (Minerval) stimulates signaling and retrograde transport
por: Torgersen, Maria L., et al.
Publicado: (2016)

Clathrin-independent endocytosis: an increasing degree of complexity
por: Sandvig, Kirsten, et al.
Publicado: (2018)

Biological response and cytotoxicity induced by lipid nanocapsules
por: Szwed, Marzena, et al.
Publicado: (2020)

Shiga Toxin Increases Formation of Clathrin-Coated Pits through Syk Kinase
por: Utskarpen, Audrun, et al.
Publicado: (2010)

Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology
por: Skotland, Tore, et al.
Publicado: (2019)

Annexin A1 and A2: Roles in Retrograde Trafficking of Shiga Toxin
por: Tcatchoff, Lionel, et al.
Publicado: (2012)

Modulation of Ricin Intoxication by the Autophagy Inhibitor EACC
por: Sandvig, Kirsten, et al.
Publicado: (2022)

Cellular effects of fluorodeoxyglucose: Global changes in the lipidome and alteration in intracellular transport
por: Kavaliauskiene, Simona, et al.
Publicado: (2016)

Interplay between Toxin Transport and Flotillin Localization
por: Pust, Sascha, et al.
Publicado: (2010)

Latest therapeutic target for gastric cancer: Anthrax toxin receptor 1
por: Sun, Ke-Ran, et al.
Publicado: (2021)

Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?
por: Tunariu, N, et al.
Publicado: (2012)

The Ether Lipid Precursor Hexadecylglycerol Causes Major Changes in the Lipidome of HEp-2 Cells
por: Bergan, Jonas, et al.
Publicado: (2013)

The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS
por: Feitz, Wouter J. C., et al.
Publicado: (2021)

Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
por: Øverbye, Anders, et al.
Publicado: (2017)

Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer
por: Pandya, Abhilash D., et al.
Publicado: (2020)

New Players in the Toxin Field: Polymorphic Toxin Systems in Bacteria
por: Jamet, Anne, et al.
Publicado: (2015)

Identification of prostate cancer biomarkers in urinary exosomes
por: Øverbye, Anders, et al.
Publicado: (2015)

Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches
por: Cakir, Merve, et al.
Publicado: (2021)

Mathematical models of targeted cancer therapy
por: Abbott, L H, et al.
Publicado: (2006)

Targeting HSP90 for cancer therapy
por: Mahalingam, D, et al.
Publicado: (2009)

Targeting glucose metabolism for cancer therapy
por: Hamanaka, Robert B., et al.
Publicado: (2012)

Targeting TNF-α for cancer therapy
por: Burton, Elizabeth R, et al.
Publicado: (2009)

B. anthracis associated cardiovascular dysfunction and shock: the potential contribution of both non-toxin and toxin components
por: Remy, Kenneth E, et al.
Publicado: (2013)

Targeting sphingosine-1-phosphate for cancer therapy
por: Sabbadini, R A
Publicado: (2006)

The telomeric PARP, tankyrases, as targets for cancer therapy
por: Seimiya, H
Publicado: (2006)

Combined targeted therapy and immunotherapy for cancer treatment
por: Guo, Cheng-Xiang, et al.
Publicado: (2021)

Rapid and quantitative detection of Shiga toxin1 and Shiga toxin2 based on multiple targets UPT‐LF assay
por: Wei, Qiaozhen, et al.
Publicado: (2020)

Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007)

Progress in the research of cuproptosis and possible targets for cancer therapy
por: Wang, Jiang, et al.
Publicado: (2023)

Shiga Toxin: Expression, Distribution, and Its Role in the Environment
por: Mauro, Steven A., et al.
Publicado: (2011)

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
por: Michelakis, E D, et al.
Publicado: (2008)

Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013)

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy
por: Jo, Ukhyun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8qdidkuob3n1e6d2tdmbl8e42f